Tozinameran (BNT162b2) Vaccine: The Journey from Preclinical Research to Clinical Trials and Authorization
Tozinameran (BNT162B2) 백신 : 전임상 연구에서 임상 시험 및 승인으로의 여정
Review
[키워드] Administered
administration
adolescents
adverse effects
age
antibody
Antibody Response
authorization
bind
BioNTech
BNT162b1
BNT162b2
BNT162b2 vaccine
BNT162b2 vaccines
children
clinical
clinical trial
clinical trials
COVID-19
dosages
Efficacy
ENCODE
EUA
exhibited
expected
expression
first dose
host cells
immune response
Immunity
individual
Lipid nanoparticle
Lipid nanoparticles
mRNA
Neutralizing antibodies
of BNT162b2
Older
operation
participant
Pfizer
Pfizer-BioNTech
Phase 1
phase 1 trials
phase 1/2 trials
Phase 2
phase 2 trials
phase 2/ 3 trials
phase 2/3
Phase 3
Phase 3 trials
Preclinical
preclinical studies
preclinical trials
pregnant
pregnant women
question
real-world outcomes
receive
reported
RNA
robust
S antigen
Safety
SARS-CoV-2
SARS-CoV-2 spike protein
speed
Spike protein
Support
the SARS-CoV-2
Tozinameran
transfer
Trial
Vaccine
[DOI] 10.1208/s12249-021-02058-y PMC 바로가기 [Article Type] Review
[DOI] 10.1208/s12249-021-02058-y PMC 바로가기 [Article Type] Review